- Home
- ONTO vs QGEN Comparison
ONTO vs QGEN Comparison
Compare ONTO & QGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ONTO | QGEN |
|---|---|---|
| Founded | 1940 | 1986 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.9B | 10.2B |
| IPO Year | N/A | 1996 |
Fundamental Metrics
Financial Performance| Metric | ONTO | QGEN |
|---|---|---|
| Price | $211.63 | $54.27 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 7 |
| Target Price | ★ $183.75 | $48.84 |
| AVG Volume (30 Days) | 728.8K | ★ 2.4M |
| Earning Date | 02-06-2026 | 02-04-2026 |
| Dividend Yield | N/A | ★ 4.33% |
| EPS Growth | N/A | ★ 331.25 |
| EPS | ★ 3.55 | 1.94 |
| Revenue | $1,002,336,000.00 | ★ $2,070,781,000.00 |
| Revenue This Year | $3.72 | $7.12 |
| Revenue Next Year | $17.29 | $5.95 |
| P/E Ratio | $60.99 | ★ $28.76 |
| Revenue Growth | ★ 6.38 | 5.32 |
| 52 Week Low | $85.88 | $39.61 |
| 52 Week High | $228.42 | $57.82 |
Technical Indicators
Market Signals| Indicator | ONTO | QGEN |
|---|---|---|
| Relative Strength Index (RSI) | 74.04 | 71.70 |
| Support Level | $176.00 | $46.07 |
| Resistance Level | $227.07 | $57.82 |
| Average True Range (ATR) | 8.55 | 1.99 |
| MACD | 2.62 | 0.89 |
| Stochastic Oscillator | 78.73 | 71.16 |
Price Performance
Historical ComparisonAbout ONTO Onto Innovation Inc.
Onto Innovation Inc is engaged in the design, development, manufacture, and support of high-performance control metrology, defect inspection, lithography, and data analysis systems used by microelectronics device manufacturers. The Company and its subsidiaries currently operate in a single operating segment. The company mainly operates in the United States, Southeast Asia, China, Japan, and Europe, with Taiwan and South Korea the sources of total revenue.
About QGEN Qiagen N.V.
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by EMEA (33%), and the Asia-Pacific (15%).